17,261 trials
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 88.9; 100.0 percentage of participants
Type 1 Diabetes Mellitus
Primary: Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia — 3 participants
Glioblastoma Multiforme
Primary: 6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B] — 0.243; 0 proportion of participants
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Evaluate Toxicity of Infusing HER2-specific T Cells as Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 — 0…
Carcinoid Tumor
Primary: Rate of Progression Free Survival (PFS) — 74.5 percentage of participants
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Maximum Tolerated Dose of Vorinostat — 500 mg twice daily X 5 days
Recurrent Adult Diffuse Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma
Primary: Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or…
Alzheimer's Disease
Primary: Number of Subjects With Non-serious and Serious Adverse Events (AEs) and Deaths — 18; 19; 22; 20 Participants
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Four Cycle Progression-free Survival Rate — 8 Participants
Various Advanced Cancer
Primary: Objective Response Rate Per BIRC Assessment — 19.6 Percent of participants
Renal Cell Carcinoma
Primary: Phase I: Maximum Tolerated Dose of BNC105P in Combination With Everolimus. — 16 mg/m^2
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Mesothelioma
Primary: Tumor Response Rate Following Zoledronic Acid (Zometa) — 12.5 percentage of responders
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Frequency of Hematologic Responses, as Defined by International Working Group (IWG) Criteria — 14; 8; 1; 7 Participants
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Successful Mobilization and Collection of PBSCs — 34 Participants